Methimazole Information
Methimazole () Description
Methimazole () tablets USP (1-methylimidazole-2-thiol) is a white, crystalline substance that is freely soluble in water. It differs chemically from the drugs of the thiouracil series primarily because it has a 5- instead of a 6-membered ring.
Each tablet contains 5 mg or 10 mg (43.8 μmol or 87.6 μmol) Methimazole () , an orally administered antithyroid drug.
Each tablet also contains anhydrous lactose, colloidal silicon dioxide, lactose monohydrate, magnesium stearate, pregelatinized starch and talc.
The molecular weight is 114.16, and the molecular formula is CHNS. The structural formula is as follows:
Methimazole () Clinical Pharmacology
Methimazole () inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodothyronine that are stored in the thyroid or circulating in the blood nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection.
The actions and use of Methimazole () are similar to those of propylthiouracil. On a weight basis, the drug is at least 10 times as potent as propylthiouracil, but Methimazole () may be less consistent in action.
Methimazole () is readily absorbed from the gastrointestinal tract. It is metabolized rapidly and requires frequent administration. Methimazole () is excreted in the urine.
In laboratory animals, various regimens that continuously suppress thyroid function and thereby increase TSH secretion result in thyroid tissue hypertrophy. Under such conditions, the appearance of thyroid and pituitary neoplasms has also been reported. Regimens that have been studied in this regard include antithyroid agents as well as dietary iodine deficiency, subtotal thyroidectomy, implantation of autonomous thyrotropic hormone-secreting pituitary tumors, and administration of chemical goitrogens.
Methimazole () Indications And Usage
Methimazole () is indicated in the medical treatment of hyperthyroidism. Long-term therapy may lead to remission of the disease. Methimazole () tablets USP may be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy. Methimazole () tablets USP are also used when thyroidectomy is contraindicated or not advisable.
Methimazole () Contraindications
Methimazole () is contraindicated in the presence of hypersensitivity to the drug and in nursing mothers because the drug is excreted in milk.
Methimazole () Warnings
Agranulocytosis is potentially a serious side effect. Patients should be instructed to report to their physicians any symptoms of agranulocytosis, such as fever or sore throat. Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) may also occur. The drug should be discontinued in the presence of agranulocytosis, aplastic anemia (pancytopenia), hepatitis, or exfoliative dermatitis. The patient's bone marrow function should be monitored.
Due to the similar hepatic toxicity profiles of Methimazole () and propylthiouracil, attention is drawn to the severe hepatic reactions which have occurred with both drugs. There have been rare reports of fulminant hepatitis, hepatic necrosis, encephalopathy, and death. Symptoms suggestive of hepatic dysfunction (anorexia, pruritus, right upper quadrant pain, etc.) should prompt evaluation of liver function. Drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality including hepatic transaminase values exceeding 3 times the upper limit of normal.
Methimazole () can cause fetal harm when administered to a pregnant woman. Methimazole () readily crosses the placental membranes and can induce goiter and even cretinism in the developing fetus. In addition, rare instances of congenital defects: aplasia cutis, as manifested by scalp defects; esophageal atresia with tracheoesophageal fistula; and choanal atresia with absent/ hypoplastic nipples, have occurred in infants born to mothers who received Methimazole () during pregnancy. If Methimazole () is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus.
Since the above congenital defects have been reported in offspring of patients treated with Methimazole () , it may be appropriate to use other agents in pregnant women requiring treatment for hyperthyroidism.
Postpartum patients receiving Methimazole () should not nurse their babies.
Methimazole () Precautions
Because Methimazole () may cause hypoprothrombinemia and bleeding, prothrombin time should be monitored during therapy with the drug, especially before surgical procedures (see ).
Periodic monitoring of thyroid function is warranted, and the finding of an elevated TSH warrants a decrease in the dosage of Methimazole () .
Methimazole () Adverse Reactions
Major adverse reactions (which occur with much less frequency than the minor adverse reactions) include inhibition of myelopoiesis (agranulocytosis, granulocytopenia, and thrombocytopenia), aplastic anemia, drug fever, a lupuslike syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. Nephritis occurs very rarely.
Minor adverse reactions include skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.
It should be noted that about 10% of patients with untreated hyperthyroidism have leukopenia (white-blood-cell count of less than 4,000/mm), often with relative granulopenia.
Methimazole () Overdosage
Symptoms may include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia (pancytopenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression. Although not well studied, Methimazole () -induced agranulocytosis is generally associated with doses of 40 mg or more in patients older than 40 years of age.
No information is available on the median lethal dose of the drug or the concentration of Methimazole () in biologic fluids associated with toxicity and/or death.
To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the “. In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.
Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. The patient's bone marrow function should be monitored. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal.
Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of Methimazole () .
Methimazole () Dosage And Administration
Methimazole () tablets USP are administered orally. Tablets are usually given in 3 equal doses at approximately 8-hour intervals.
Methimazole () How Supplied
Methimazole () Tablets USP for oral administration are available as:
The 5 mg tablets are white, round, biconvex, beveled tablets, scored on one side and debossed “” over “205” on the other. They are available as follows:
Unit dose packages of 100 (10x10)
NDC 68084-275-01
The 10 mg tablets are white, round, biconvex, beveled tablets, scored on one side and debossed “” over “210” on the other. They are available as follows:
Unit dose packages of 100 (10x10)
NDC 68084-276-01
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.
Sandoz Inc.Princeton, NJ 08540
Repackaged by:American Health PackagingColumbus, Ohio 43217
8227601/0306
Methimazole () Methimazole Tablets Usp, Mg Tablets - Label
Methimazole () Methimazole Tablets Usp, Mg Tablets - Label
